Apimeds Pharmaceuticals US Other Current Liabilities

Apimeds Pharmaceuticals US (APUS) currently reports a other current liabilities of $6.6M as of June 2026. That compares with $310K in the prior-year period — up 2034.2% year over year. Use the charts on this page to explore Apimeds Pharmaceuticals US's other current liabilities history and peer comparisons.

Apimeds Pharmaceuticals US's other current liabilities increased from $310K to $6.6M — a 2034.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Apimeds Pharmaceuticals US reported $6.6M in other current liabilities as of June 2026. That compares with $310K in the prior-year period — up 2034.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $6.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Apimeds Pharmaceuticals US, and consider following APUS for alerts when major investors trade the stock.